Search by Drug Name or NDC
NDC 50228-0175-30 Bupropion Hydrochloride 150 mg/1 Details
Bupropion Hydrochloride 150 mg/1
Bupropion Hydrochloride is a ORAL TABLET, FILM COATED, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ScieGen Pharmaceuticals, Inc.. The primary component is BUPROPION HYDROCHLORIDE.
MedlinePlus Drug Summary
Bupropion (Aplenzin, Wellbutrin, Wellbutrin SR, Wellbutrin XL) is used to treat depression. Bupropion (Aplenzin, Wellbutrin XL) is also used to treat seasonal affective disorder (SAD; episodes of depression that occur at the same time each year [usually in the fall and winter but rarely may occur in the spring or summer months]). Bupropion (Zyban) is used to help people stop smoking. Bupropion is in a class of medications called antidepressants. It works by increasing certain types of activity in the brain.
Related Packages: 50228-0175-30Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Bupropion
Product Information
| NDC | 50228-0175 |
|---|---|
| Product ID | 50228-175_0e365624-304c-4884-e063-6294a90ad54f |
| Associated GPIs | 58300040107430 |
| GCN Sequence Number | 046238 |
| GCN Sequence Number Description | bupropion HCl TAB SR 12H 150 MG ORAL |
| HIC3 | H7D |
| HIC3 Description | NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIB (NDRIS) |
| GCN | 16386 |
| HICL Sequence Number | 001653 |
| HICL Sequence Number Description | BUPROPION HCL |
| Brand/Generic | Generic |
| Proprietary Name | Bupropion Hydrochloride |
| Proprietary Name Suffix | SR |
| Non-Proprietary Name | bupropion hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 150 |
| Active Ingredient Units | mg/1 |
| Substance Name | BUPROPION HYDROCHLORIDE |
| Labeler Name | ScieGen Pharmaceuticals, Inc. |
| Pharmaceutical Class | Aminoketone [EPC], Dopamine Uptake Inhibitors [MoA], Increased Dopamine Activity [PE], Increased Norepinephrine Activity [PE], Norepinephrine Uptake Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA205794 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 50228-0175-30 (50228017530)
| NDC Package Code | 50228-175-30 |
|---|---|
| Billing NDC | 50228017530 |
| Package | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50228-175-30) |
| Marketing Start Date | 2018-04-20 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |